Psychoactive Substances Bill [HL]

Baroness Meacher Excerpts

Tuesday 14th July 2015 Lords Chamber

Moved by

[Baroness Meacher]

1: Clause 1, page 1, line 3, after “about” insert “synthetic”

[Baroness Meacher (CB)]

My Lords, the contents of Amendment 1 are reflected in Amendment 3. I am grateful to my noble friend Lord Rees, the noble Lords, Lord Norton and Lord Howarth, and my noble friend, if I may call her that, Lady Hamwee, for putting their names to one or other of those amendments. My noble friend Lord Patel also wanted to add his name to one or other of the amendments but unfortunately the lists were full. I simply want to make the point about the breadth of support for the amendments.

The purpose of the amendments is to limit the scope of a blanket ban to synthetic psychoactive substances. That raises two issues: should we seek to limit the scope of the blanket ban at all; and, if we should, is the word “synthetic” the right one? I will not repeat what I or others said in Committee, but will refer to events since—there have been a number.

On the first point, since Committee, overwhelming support has emerged for limiting the scope of the blanket ban. As the Minister knows, the Government’s Advisory Council on the Misuse of Drugs makes very clear in a letter to the Home Secretary that it cautions against a blanket ban on all psychoactive substances. The ACMD points out:

“It is almost impossible to list all possible desirable exemptions under the Bill. As drafted, the Bill may now include substances that are benign or even helpful to people including evidence-based herbal remedies that are not included on the current exemption list”.

The Minister will also be aware of the letter to the Prime Minister published in the Times from the former Archbishop of Canterbury—one cannot go a lot higher than that—among other eminent academics and ethicists. They say:

“It is not possible to legislate against all psychoactive agents without criminalising the sale of harmless, everyday products that produce changes in mood”.

I very much hope that the Home Secretary will heed the advice of those many experts.

The second point raised by the amendment is why we use the term “synthetic” to define the ban on psychoactive substances. I believe I am right in saying that the Conservative manifesto referred to a ban on legal highs. In tabling the amendment, I assure the House that we seek to respect the Government’s manifesto commitment. However, the term “legal high” is, I am told, not appropriate for legislation. There is consensus among the experts that the target of the Bill should indeed be legal highs. The ACMD uses the word “novel”, and I shall quote a short paragraph from the ACMD letter on the issue. It states:

“The ACMD would support a ‘blanket ban’ on Novel Psychoactive Substances, but cautions against a blanket ban on all psychoactive substances”.

I have very good reason to believe that the ACMD would be entirely happy with the term “synthetic psychoactive substances” in place of the word “novel” to define a legal high. For me, that is very important.

At a meeting with a top professor of neuropsychopharmacology and a QC, we discussed the relative merits of the words “novel”, “new” and “synthetic” in this context. It was agreed that neither the term “novel” nor the term “new” would be recognised in a court of law. We have many lawyers here, and I am sure they will tell me if my legal adviser is wrong or right. Mr Fortson QC was very clear on this point. He said that the best term to define legal highs and thus to honour the Conservative manifesto commitment would be “synthetic psychoactive substances”. The following sets out what we agreed as drafted by one of those experts:

“We recommend that the target of the Bill be amended to define the banned substances as synthetic psychoactive substances. This will at a stroke eliminate the requirement for many innocuous psychoactive botanicals to be exempted, eg, perfumes, incense, herbal remedies”.

I believe that there could be many hundreds, perhaps thousands more. In particular, it will cover all current and future synthetic cannabis analogues, which are proving such a huge problem in prisons and elsewhere.

The only botanicals currently used recreationally that might currently pose any concern—I emphasise “any”—are kratom and salvia. However, they are not reported to lead to deaths or public disorder and, if they became more of a concern, they could readily be controlled under the Misuse of Drugs Act 1971. The point about botanical substances is that it takes years to create a new one. The Bill is designed to control synthetic substances, a new one of which can be created in a matter of minutes. The need is to find a definition of banned substances that is proportionate, ensuring that the Government avoid banning all sorts of harmless products and cause untold problems for manufacturers, shops and consumers, while spreading the blanket ban widely enough to catch all harmful synthetic substances—that is, those substances not controlled by the Misuse of Drugs Act.

On this point, I should notify Ministers and the House that I plan to table a tidying-up amendment at Third Reading to bring all synthetic psychoactive substances currently controlled under the Misuse of Drugs Act under the control of this legislation. It makes no sense to have hundreds of synthetic psychoactive substances controlled under one Act, while any new psychoactive substance would be controlled under different legislation —that is, this Bill. I hope very much that that amendment at Third Reading will not be controversial.

--- Later in debate ---

[Lord Bates]

I ask the noble Lord please not to go to the other side just yet but to stay with me a little longer. I was referring to the amendment of the noble Lord, Lord Paddick, and was talking about the use of the term “novel” in this context. That was the ACMD point, as opposed to the point about the use of “synthetic”, which I shall come to later and have already touched upon. Now the noble Lord, Lord Paddick, looks puzzled; perhaps I have lost him in gaining the noble Lord, Lord Tunnicliffe. Perhaps I may continue with what I was saying and then I will come to the specific point raised by the noble Lord.

I accept that while our target in this Bill is substances that are harmful when misused, or which have the potential to cause harm, the Bill seeks to define the effect of these substances rather than to make any explicit reference to their harms. Of course, the advisory council has a considerable and impressive track record in making these harm assessments. It is a scientific body of experts which for the last 40 years has been advising successive Governments. These amendments would require assessments of individual substances, or even groups of substances, for the purpose of bringing them within the scope of the Bill and its offences.

Our fundamental issue with that is that it would perpetuate the inadequacies and frustrations of our current approach under the 1971 Act. As the expert panel found, a substance-by-substance approach would not meet our core objective to get fully ahead of the market and scientific developments. It would allow the suppliers to adapt their range of substances on sale in response to new controls. That is exactly what has happened in the past and is behind the purpose of this legislation. Indeed, by driving innovation in the market, the current approach adds to the harms caused by these substances, as each new generation of psychoactive substances is more potent than the last. We need a change in gear—that is what the blanket ban will deliver.

Finally, Amendment 9 adopts a different approach again to how we define a psychoactive substance for the purposes of the Bill. Clause 3 enables the Home Secretary to make regulations, subject to the affirmative procedure, which add to or vary the list of exempted substances in Schedule 1. As we have previously debated, the regulation-making power in Clause 3 has been designed to future-proof the list of exempted substances and ensure that, for example, medicinal products are not inadvertently caught by the blanket ban provided for in the Bill. Schedule 1 contains broad categories of established substances and products that we want to exclude from this regime, mostly because they are already regulated by other legislation.

I turn to the specific point put to me by the noble Lord, Lord Tunnicliffe. He pointed to the advisory council’s concerns about proving psychoactivity as a point of law. I wrote to the noble Lord on this very issue, and he quoted my letter, in which I said:

“The Government is committed to supporting the law enforcement community in the exercise of their powers under the Bill. We will work with the national policing lead and College of Policing on the development of policing guidance”.

It is important to recognise that different powers in the Bill apply to different standards of proof. For example, the powers of seizure in Clause 42 operate to a “reasonable belief” test. An officer’s reasonable belief that a substance is psychoactive could be based on a number of factors, including the substance’s packaging, its markings or even whether the individual from whom it was seized appeared intoxicated and the officer could infer that the substance found might be responsible. The same “reasonable belief” test applies to the issuing of a prohibition notice or a premises notice. Applications for prohibition orders and premises orders are determined on the basis of the balance of probabilities.

In the case of a prosecution for an offence under Clauses 4 to 8—I think that this comes to the point that the noble Lord invited us to look at—we have the criminal test of “beyond reasonable doubt”. Clause 25, which is referred to in my letter, deals with the offence of failing to comply with a prohibition order or premises order. That clearly involves the civil test of the balance of probabilities. However, failure to comply with the order can involve a criminal sanction. Therefore, quite rightly the noble Lord came back and asked whether it was possible that we could end up with someone being caught between the two tests—the civil and the criminal—and facing a criminal sanction on the balance of probabilities test. As I understand it, that is at the heart of his concern. I can certainly give him the assurance that before any criminal sanction could be made under Clause 25, there would need to be proof to the criminal standard of “beyond reasonable doubt” that the substance involved was indeed psychoactive.

I hope that that clarification will help the noble Lord, Lord Tunnicliffe, with his concerns. I also hope that the point that I made right at the beginning to the noble Baroness, Lady Meacher, that we are continuing in a genuine dialogue with the Advisory Committee on the Misuse of Drugs, will allow her to—

[Baroness Meacher]

Before the Minister sits down, I would like to put one question to him on that issue. He said at the beginning that he was not ruling out the term “synthetic”, but I then became very confused when he started talking about a number of botanicals. Does he agree that there is in fact great value in separating the machinery for botanical substances, which are developed over many years and which can be brought under the Misuse of Drugs Act if they are dangerous—harmful—from synthetic substances, which need a rather different kind of machinery? I think that the Minister was indicating that there are botanical substances that may be to some degree harmful.

Of course the police are able to use common sense. They tend not to arrest and criminalise the possession of herbal cannabis. They will know that it is infinitely less dangerous than something such as alcohol. The same would apply to other botanical substances developed over many years. If they were brought under the Misuse of Drugs Act, which the Minister referred to as rather draconian, that Act also could be used with a degree of common sense. I want to be clear whether the Minister accepts the great value of separating these two completely different sets of substances.

[Lord Bates]

The noble Baroness goes to the heart of the issue; we have a problem with that. We are just not convinced. There are botanicals, to which we have referred. There are other substances, such as nitrous oxide. Does “synthetic” as a term cover what we want it to cover, or will we be reassembled back here at some future date trying to clamp down on another loophole which has been exploited? That is the difficulty. When I say that I am not ruling out the term “synthetic”, that is absolutely correct, but we want to make sure that if the term is used, it is understood in a legal context as achieving the intention of the Bill, which is to uphold a blanket ban. I hope that, with that, I have provided some clarification.

--- Later in debate ---

[Lord Bates]

In responding on the Bill, I gave a number of examples of particular botanical substances that would fail the test of “synthetic”. Therefore, it is very much as my noble and learned friend has said. Those substances do not meet the harm threshold of the 1971 Act, but some natural substances are controlled under it. This is part of the confusion and discussion that is still to be resolved, but we believe that what we have at the moment is clear in terms of the intent of the Bill and that to insert “synthetic” at this stage would unnecessarily limit the scope of the Bill and potentially open up new loopholes, which would need to be closed down legislatively on another occasion.

[Baroness Meacher]

My Lords, I thank all noble Lords who have contributed to this debate. It has turned into an incredibly wide-ranging, constructive and interesting debate, so I am most grateful to all noble Lords. I want to pick up in particular on the comments made by the noble and learned Lord, Lord Mackay. His initial comment was that he had no problem with the word “synthetic” and then introduced a very interesting point: that the intention behind a substance is very pertinent. Interestingly, he raised a similar point in writing to the chairman of the ACMD, saying that this would be a helpful addition to the definition of a synthetic psychoactive substance. If you bring in the intention behind the substance, then you have really got it. I am very grateful to the noble and learned Lord for that contribution.

Things became a bit more confused a little later, because if a botanical substance is treated and becomes a psychoactive substance it would automatically come within the definition of synthetic psychoactive substance. That is the purpose of the amendment: to keep a separation between genuinely botanical products, which take years to develop and produce and which can very properly be controlled under the Misuse of Drugs Act, and those substances which are treated, and can be treated rather quickly, to create another synthetic psychoactive substance. Those latter should be brought under the control of this legislation. It seems to me that we can produce two sets of very logical, useful legislation to deal with those two completely different types of substance. They might have similar effects, but their production and its timeframe are entirely different. They have to be treated differently under the law. I wanted to make that position clear bearing in mind the points made by the Minister, who said that he was not ruling out the use of “synthetic” but then raised some rather serious questions about whether he could introduce “synthetic” to define psychoactive substances covered by this Bill.

The crucial point here is that the Irish experience shows that you cannot assess whether a substance is psychoactive without using human beings to test it. It has not worked in Ireland. Dealing with the matter in the way that we have suggested in the amendment is a great deal better than they have managed to do in Ireland.

I hope I have managed to thank everybody adequately. I also thank the Minister for his meetings with me and, in particular, for the very helpful meeting we had yesterday. Only because I know that the ACMD supports us in this amendment and now feel confident that the Government will have serious discussions with the council about this issue, and because I am therefore confident that the Government will find their way to doing the sensible thing and having this clear division between botanicals and synthetics, I am prepared to withdraw my amendment.

Amendment 1 withdrawn.

--- Later in debate ---

Moved by

[Baroness Meacher]

11: Schedule 1, page 37, line 7, leave out paragraph 2 and insert—
“2 All medicinal products prescribed by a doctor or sold by a licensed pharmacist.”

--- Later in debate ---

[Baroness Meacher]

My Lords, in moving Amendment 11 I shall also speak to Amendment 12, both of which we debated in Committee. I intend not to repeat anything of the arguments we used then but rather to reflect on developments since. The intention of the amendments is to ensure that all legitimate medicines and substances used for any form of legitimate research are exempted from the scope of this legislation.

I am most grateful for the Minister’s letter to the noble Lord, Lord Rosser, in which he says that the Government are looking again at the definition of medicinal products in Schedule 1 to ensure that it is fully aligned with existing medicines legislation. The question is what exactly that means. I seek only an assurance from the Minister that the definition will include all medicines prescribed on a named-patient basis and all unlicensed—or any other—psychoactive substances prescribed by a doctor on the basis that the prescription is believed by that doctor to be in the best interests of the patient. My clear understanding is that a doctor can prescribe any medication, even if it is unlicensed or not recognised, so long as they believe that it will help the patient. Many medicines come on to the market which may have been tested in other countries or in other ways but which have not been through UK systems.

Amendment 12 deals with research. It would be helpful to have an assurance that all legitimate research, including laboratory research, involving psychoactive substances in academic institutions or undertaken by industry will be fully exempted from the scope of the Bill. Alternatively, perhaps the Minister could assure the House that the Government will seek an assurance from the ACMD that whatever wording is used will achieve that objective. We just want all noble Lords to be completely satisfied that these two objectives will be achieved.

I have added my name to Amendment 24, tabled by the noble Lord, Lord Paddick. The aim here, as I understand it, would be to ensure that the regulations exempting medicines and research are in place by the implementation date of the legislation. The wording in the amendment itself is slightly different, but I am sure that that is the intention. No doubt the Minister will comment on this in her response to this group of amendments.

[Baroness Hamwee]

My Lords, Amendment 24, to which the noble Baroness has added her name, comes from my noble friend Lord Paddick and me. Like the noble Baroness, I will not spend long on this, because I am optimistic about where the Government are going with it. I was concerned that the current provisions of the Bill are too limited, because they are limited to medicines. However, I will repeat one comment that I made at the last stage. Professor Val Curran, in her report for the all-party parliamentary group that the noble Baroness chairs on regulating cannabis for medicinal use, referred to a “stranglehold on research”. She sets out, quite pithily, the “costly obstacle course” involved in undertaking any research, because of the time taken by licence applications. Import licences are being granted for so short a time that they expire before the arrangements for the research can be made, so I welcome the Government’s further consideration of this. As Professor Curran says, at the moment, UK research into this area is a “massive uphill struggle”.

--- Later in debate ---

[Baroness Chisholm of Owlpen (Con)]

I thank noble Lords for all their points. As discussed in Committee, there is common ground between these amendments and the Government’s position. As I said in Committee, it is the Government’s absolute and determined objective that bona fide medical and scientific research should be untouched by the provisions of the Bill. We will deal with the issue of research on cannabis when we reach Amendment 25.

It is already the case that broad swathes of research involving psychoactive substances fall outside the blanket ban. If a substance is not intended for human consumption for its psychoactive effects, it will not be caught by the Bill. Paragraph 3 of Schedule 1 exempts investigational medicinal products used in clinical trials. However, I understand, and the Government fully accept, that this exemption does not go far enough. This is an issue of some concern for the academic and scientific community. The noble Baroness, Lady Meacher, referred in Committee and again today to the letter in support of her Amendment 12 sent to my right honourable friend the Home Secretary by the Academy of Medical Sciences and five other leading scientific institutions. My noble friend Lord Bates responded to that letter yesterday. I shall read out the critical paragraph in that response:

“We have now had some further discussions with the Department of Health and the Medical Research Council. In going forward, we need to ensure that any amendment to the Bill satisfies the scientific community as represented by the Academy of Medical Sciences and your co-signatories, as well as our own policy and legislative requirements. For this reason, we intend to develop this work in the coming weeks with a view to introducing an amendment when the Bill is considered by the House of Commons. To help achieve this I would value engagement between your representatives and officials from both the Home Office and the Department of Health to reach a common understanding and satisfactory outcome in the next few weeks”.

I hope that that will reassure noble Lords that we are firmly committed to bringing forward an appropriate amendment on this issue, but it will take more time to get it right in consultation with the Academy of Medical Sciences, the Advisory Council on the Misuse of Drugs and others. We need to ensure that bona fide medical and scientific research is excluded from the ambit of the Bill, while not creating a loophole for others, whose only purpose is the recreational use of psychoactive substances, to exploit.

Amendment 11 is on a different point raised by the noble Baroness, Lady Meacher, in seeking to expand the definition of medicinal products, and therefore the exemption for such products, in paragraph 2 of Schedule 1. The noble Baroness is pushing at an open door here. As I also indicated in Committee, this is another area we are considering further with the Department of Health and the Medicines and Healthcare Products Regulatory Agency.

We are conscious that the Bill as drafted does not include unlicensed medicines for human use known as “specials”. These are lawfully manufactured, imported, distributed or supplied for the treatment of individual patients after being ordered by a range of healthcare professionals, not just doctors. As such, they need to be taken out of scope of the definition of a psychoactive substance.

In its letter to the Home Secretary, the Advisory Council on the Misuse of Drugs specifically raised concerns about the scope of exemption for herbal medicines. The European Herbal & Traditional Medicine Practitioners Association has also flagged a need to ensure that the exemption for medicines includes herbal medicines used by practitioners on a named-patient basis. This is another area where we are actively reviewing whether we need to adjust the current definitions in the Bill.

Medicines legislation is a complex area, as I know noble Lords are aware, and defining bona fide research is not as straightforward as one might imagine. We have certainly not so far been able to identify an off-the-shelf definition in existing legislation which we can readily apply. It is regrettable that we have not been able to table amendments in time for the House today, and I fear we will not be in a position to do so for Third Reading next Monday. I ask noble Lords to bear with us. We will use the time over the Summer Recess—no holidays for us—to bring forward appropriate amendments in the Commons. I will ensure that noble Lords taking part in this debate have sight of those amendments. Your Lordships’ House will then have an opportunity to consider the issue further when the Bill returns from the Commons in the autumn.

I hope that, in the light of that commitment, the noble Baroness, Lady Meacher, will be content to withdraw her amendment.

[Baroness Meacher]

My Lords, I thank noble Lords who have spoken in this debate. I thank the Minister for her reassuring comments, her assurance about the Government’s commitment to ensuring that all bona fide medicines and research will fall outside the scope of the Bill, and her assurance that the Government will consult key experts to ensure that the Bill is right in this respect. On that basis, I beg leave to withdraw the amendment.

Amendment 11 withdrawn.

--- Later in debate ---

[Lord Paddick]

My Lords, my noble friend Lady Hamwee and I have Amendment 16 in this group, which approaches the issue from a slightly different position. Our amendment suggests that:

“It shall be a defence that the person did not supply the substance for gain”.

The difference here is that as I understand it, the amendment in the name of the noble Lord, Lord Howarth, would mean that the prosecution would have to prove that this was the case, whereas in our case, if it was a defence, it would be a matter for the accused person to prove that they did not supply the substance for gain. As the noble Lord, Lord Howarth, said, on page 3, point 5, of the ACMD’s letter of 2 July, for very similar reasons it is not only concerned that this will criminalise,

“otherwise law abiding young people and adults”,

but concerned with regard to the discriminatory impact.

The Secretary of State is encouraging in her response to the letter, saying that,

“the police and Crown Prosecution Service will exercise their professional discretion taking into all the circumstances of the offence and the offender”.

However, the concern—which is not addressed by the Secretary of State, but is expressed by the advisory council—is that it is not simply a case of members of the black and minority-ethnic community being disproportionately stopped and searched by the police, which the Secretary of State addresses in her response, but that members of the black and minority-ethnic community are disproportionally more likely to be charged rather than cautioned for an offence. They are also disproportionally likely to have a formal disposal of their case rather than no further action being taken.

Therefore, while the Secretary of State’s efforts to improve the police’s use of stop and search is to be applauded, she does not address the other issues regarding the fact that members of that group are disproportionately more likely to face a form of sanction, be it a caution rather than no further action, and more likely to be charged with an offence rather than given a caution, bearing in mind that the Secretary of State says that out-of-court disposals would be used in “appropriate cases”. Our concern is that without it being a statutory defence, with the burden of proof lying on the accused, there is regrettably—to judge by evidence of what has happened in the past—a danger that the powers in the Bill will disproportionately affect black and minority-ethnic communities and will therefore discriminate against them, as the advisory council’s letter points out.

[Baroness Meacher]

My Lords, all that needs to be said has been said. I will simply express my support for these amendments, on the grounds that for a child of 14 to get a criminal record will be far more serious for them than any damage that might be done by some rather dubious psychoactive substance. That is not to say that I in any way support young people taking these things, but we know that they do. All the literature— certainly that from Portugal—suggests that avoiding a criminal record is an enormous plus for a young person; they are much more likely to remain with their studies and get a job when they leave school. It is therefore a very serious matter to include these activities, whether it is sharing a substance with a group of friends or some such activity. The Government designate such an activity as a criminal offence at their peril in terms of the longer-term consequences, as well as the probable long-term costs to the Government, of dysfunctional young people, unemployed people and people getting into a criminal lifestyle.

[Lord Ramsbotham]

My Lords, I, too, support these amendments but for a slightly different reason. I have a Private Member’s Bill, which I hope will come forward, to amend the Rehabilitation of Offenders Act. In it is something that I found when inspecting the prisons in Barbados. I found that at the age of 18 everyone’s criminal record was examined and everything except for violent and sexual offences was expunged so that a child did not take forward a criminal record after that age. I mention this merely because I think we ought to take very seriously the matter of people—particularly young people—taking forward into later life an early criminal record.